Key result
Percutaneous endomyocardial ablation shows unclear benefit as septal reduction therapy in obstructive HCM.
Why the study?
Hypertrophic cardiomyopathy causes dynamic LVOT obstruction due to multifactorial mechanisms including septal hypertrophy and mitral valve abnormalities, necessitating evaluation of septal reduction strategies.
Observational
No
Observational study reports outcomes of percutaneous endomyocardial ablation in obstructive hypertrophic cardiomyopathy, indicating its role in relieving dynamic outflow tract obstruction.
Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disorder characterized by unexplained left ventricular hypertrophy and a prevalence of approximately 1:500 in the general population.1,2 Dynamic left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients under resting or provoked conditions.3 Obstruction is multifactorial and results from septal hypertrophy, altered mitral valve geometry, and systolic anterior motion of the mitral valve.3,4 Although systolic anterior motion contributes to obstruction, it is not invariably the sole mechanism.
No takes yet. Share an insight, caveat, or question.
Casey et al. (2026) conducted an observational in Symptomatic obstructive hypertrophic cardiomyopathy. Percutaneous endomyocardial ablation was evaluated. Percutaneous endomyocardial ablation was evaluated as a septal reduction strategy for symptomatic obstructive hypertrophic cardiomyopathy, but no quantitative results were provided in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: